Linkedin
RLS logo_header
Linkedin

CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Gen Dual-Payload ADCs

“We look forward to seeing how Lilly advances our new generation of dual-payload antibody-drug conjugates, including CBB-120, with the potential to meaningfully improve outcomes for patients with limited treatment options. At CrossBridge Bio, we believe our dual-payload ADC platform is uniquely positioned to be transformative in oncology. I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding. By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach,” said Dr. Michael Torres, Co-Founder and CEO.

Read the full story on "CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Gen Dual-Payload ADCs"

Share:

More News

Gotistobart Nearly Doubled Median OS versus SOC Chemo in Previously Treated Squamous NSCLC Patients

“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel

Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program

“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated

Zipalertinib + chemo Demonstrates 6-Month Median PFS Benefit in REZILIENT3 Ph 3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC

“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with

FDA clears IND application to initiate Ph 1 study for PRT13722 for HR+/HER2- breast cancer patients

“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines